
Covalent Inhibition of Botulinum Neurotoxin A




Exploration of Warhead Reactivity and Function Using a Bifunctional Approach



Background

• Botulinum neurotoxins (BoNTs), produced by *Clostridium Botulinum*, are the most potent known toxins.


- BoNT/A has an intravenous LD₅₀ of 1–2 ng/kg and has an extremely long half-life (months)
- Used for a plethora of therapeutics but also high potential for bioterrorism
- Catalytic activity stems from the light chain (LC) through its selective cleavage of SNAP-25. The LC is a zinc metalloprotease and is a target for metal-binding small-molecule inhibitors
- Currently, no known small-molecule therapeutics exist for the treatment of BoNT/A intoxication




BoNT/A LC crystallised with small molecule inhibitor DCHA (PDB: 2IMA)

Hypothesis and Previous Work

- Covalent inhibition has potential to abrogate BoNT/As innate longevity and remove need for long-term dosing
- Previous work¹ demonstrated that Cys165 can be covalently modified by a small electrophilic molecule (MTSEA)
- Current best-in-class inhibitor DCHA binds zinc through hydroxamate in a bidentate fashion
- Hybridization of both strategies² resulted in 1 that was shown to inhibit BoNT/A LC in a bifunctional manner
- Methanethiosulfonate (MTS) warhead is highly reactive and unsuitable for therapeutic use









Overlay of DCHA (PDB: 2IMA) and MTSEA (PDB: 4ELC) BoNT/A LC crystal structures

Chemistry and Biological Evaluation



Stability and Cellular Evaluation



RSC Lysate Assay

BoNT/A

μΜ

30

32

μΜ

36

36

BoNT/A

 Poor cellular potency attributed to poor permeability of hydroxamate-based compounds

Moderate response in cells but did not illicit

⊘ Scripps Research

the desired potency

Conclusion, Future Work and Acknowledgements

- Several warhead types were shown to bind covalently to BoNT/A LC with epoxide-containing 36 forming a proximity-based covalent bond.
- A trend in compound reactivity reflected stability and toxicity profiles
- Hydroxamate-based compounds did not furnish the desired cellular potency, however, a fundamental framework for the bifunctional covalent inhibition of BoNT/A LC has been established.
- This strategy will be incorporated into other metalchelating pharmacophores for the inhibition of BoNT/A:

3,4 - HOPTO

⊘ Scripps Research

Lin et al, RSC Med. Chem., 2020, Advance Article

Janda Lab members

Alexander Nielsen*

Lucy Lin*
Dr. Lisa Eubanks

Dr. Margaret Olson

Dr. Takashi Sugane

Prof. Kim Janda

Collaborators

Dr. Sabine Pellett

Email:

Iturner@scripps.edu



Myself, Alex and Lucy aka 'The BoNT Bros'